alexa Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Diabetes & Metabolism

Author(s): Seed A, Gardner R, McMurray J, Hillier C, Murdoch D,

Abstract Share this page

Abstract BACKGROUND: Suppression of the renin-angiotensin-aldosterone system (RAAS) is therapeutically valuable in chronic heart failure (CHF). RAAS inhibition can be achieved in a number of ways though an orally active renin inhibitor (RI) has never been studied before. We describe the neurohumoral effects of an RI. METHODS AND RESULTS: 27 patients with NYHA class II or III CHF and an ejection fraction
  • DOI: 10.1016/j.ejheart.2007.09.002
  • This article was published in Eur J Heart Fail and referenced in Journal of Diabetes & Metabolism

    Relevant Expert PPTs

    Relevant Speaker PPTs

    Recommended Conferences

    Relevant Topics

    Peer Reviewed Journals
     
    Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
    International Conferences 2017-18
     
    Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

    Contact Us

     
    © 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
    adwords